TY - JOUR
T1 - Effect modification by transferrin C2 polymorphism on lead exposure, hemoglobin levels, and IQ
AU - Roy, Ananya
AU - Ettinger, Adrienne S.
AU - Hu, Howard
AU - Bellinger, David
AU - Schwartz, Joel
AU - Modali, Rama
AU - Wright, Robert O.
AU - Palaniappan, Kavitha
AU - Balakrishnan, Kalpana
N1 - Funding Information:
We would like to acknowledge the efforts of the staff at Sri Ramachandra Medical College in collecting and coordinating the information gathered for this study. Financial support was provided by U.S. National Institute of Health (NIH) grant numbers: R03TW005914 , R01ES007821 and R01ES021446 .
PY - 2013/9
Y1 - 2013/9
N2 - Background: Iron deficiency and lead exposure remain significant public health issues in many parts of the world and are both independently associated with neurocognitive deficits. Polymorphisms in iron transport pathways have been shown to modify the absorption and toxicity of lead. Objective: We hypothesized that the transferrin (TF) C2 polymorphism modifies the effects of lead and hemoglobin on intelligence. Methods: Children aged 3-7 years (N= 708) were enrolled from 12 primary schools in Chennai, India. The Binet-Kamath Scale of Intelligence were administered to ascertain intelligence quotient (IQ). Venous blood was analyzed for lead and hemoglobin levels. Genotyping for the TF C2 polymorphism (rs1049296) was carried out using a MassARRAY iPLEXTM platform. Stratified analyses and interaction models, using generalized estimating equations, were examined to explore interactions between lead, hemoglobin, and TF C2 categories. Results: A one-unit increase in log blood lead and 1. g/dl higher hemoglobin was associated with -77 (95% CI: -136, -18) and 17 (95% CI 14, 21) IQ points, respectively, among children carrying the C2 variant. In comparison, among children who had the homozygous wildtype allele, the same increment of lead and hemoglobin were associated with -21(95% CI: -65, 24) and 28 (95% CI: 15, 40) IQ points, respectively. There was a significant interaction between lead (p= 0.04) and hemoglobin (p= 0.07) with the C2 variant. Conclusion: Children who carry the TF C2 variant may be more susceptible to the neurotoxic effects of lead exposure and less protected by higher levels of hemoglobin.
AB - Background: Iron deficiency and lead exposure remain significant public health issues in many parts of the world and are both independently associated with neurocognitive deficits. Polymorphisms in iron transport pathways have been shown to modify the absorption and toxicity of lead. Objective: We hypothesized that the transferrin (TF) C2 polymorphism modifies the effects of lead and hemoglobin on intelligence. Methods: Children aged 3-7 years (N= 708) were enrolled from 12 primary schools in Chennai, India. The Binet-Kamath Scale of Intelligence were administered to ascertain intelligence quotient (IQ). Venous blood was analyzed for lead and hemoglobin levels. Genotyping for the TF C2 polymorphism (rs1049296) was carried out using a MassARRAY iPLEXTM platform. Stratified analyses and interaction models, using generalized estimating equations, were examined to explore interactions between lead, hemoglobin, and TF C2 categories. Results: A one-unit increase in log blood lead and 1. g/dl higher hemoglobin was associated with -77 (95% CI: -136, -18) and 17 (95% CI 14, 21) IQ points, respectively, among children carrying the C2 variant. In comparison, among children who had the homozygous wildtype allele, the same increment of lead and hemoglobin were associated with -21(95% CI: -65, 24) and 28 (95% CI: 15, 40) IQ points, respectively. There was a significant interaction between lead (p= 0.04) and hemoglobin (p= 0.07) with the C2 variant. Conclusion: Children who carry the TF C2 variant may be more susceptible to the neurotoxic effects of lead exposure and less protected by higher levels of hemoglobin.
KW - Genotype
KW - Hemoglobin
KW - Intelligence quotient (IQ)
KW - Iron
KW - Lead
KW - Transferrin
UR - https://www.scopus.com/pages/publications/84879561158
U2 - 10.1016/j.neuro.2013.05.005
DO - 10.1016/j.neuro.2013.05.005
M3 - Article
C2 - 23732512
AN - SCOPUS:84879561158
SN - 0161-813X
VL - 38
SP - 17
EP - 22
JO - NeuroToxicology
JF - NeuroToxicology
ER -